Scienture Holdings Inc (SCNX) News

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form EFFECT - Notice of Effectiveness

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form DEF 14A - Other definitive proxy statements

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

TAMPA, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a Specialty Pharma...

Form 8-K - Current report

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

Form DEF 14C - Other definitive information statements

Form PRE 14C - Other preliminary information statements

Form D - Notice of Exempt Offering of Securities

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the “Company”) (NASDAQ: SCNX), a...

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC (“the “Company”), a wholly owned...